1 suspended. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Suspended 1 |
Follow relatlimab: new trials by email Literature Review of relatlimab trials Research Report on relatlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 184 | 2024-11-08 | 2026-10-30 |
Glioblastoma (1)
National Cancer Institute (NCI) (1)
United States (1)
Michael Lim (1)
U10CA180821 (1)